ACRS — Aclaris Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1557746 ·
Last close
$4.51
Market Cap
$629.88M
52W High
$5.15
52W Low
$2.75
ADV30
1,361,118
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,996,000 | 208,000 | -22,192,000 | -19,824,000 | 198,720,000 | 28,660,000 | 55,071,000 |
| Dec 2025 | 1,295,000 | -174,000 | -21,029,000 | -19,795,000 | 160,460,000 | 19,960,000 | 57,378,000 |
| Sep 2025 | 3,299,000 | 850,000 | -16,333,000 | -14,614,000 | 175,534,000 | 25,256,000 | 55,434,000 |
| Jun 2025 | 1,777,000 | -73,000 | -15,947,000 | -15,429,000 | 189,147,000 | 25,402,000 | 57,408,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-47,113,000
Investing CF
$48,365,000
Financing CF
$-5,862,000
CapEx
$-36,731,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.53
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-967,784,000
Inventory
—
Receivables
$4,680,000
ST Investments
$70,791,000
EBIT TTM
$-70,260,000
Pretax Income TTM
$-64,923,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$8,367,000
EBITDA
$-78,469,000
Free Cash Flow
$-32,210,876
Enterprise Value
$526,452,192
Total Cash
$105,416,000
Total Debt
$1,985,000
Shares Out
139,663,680
Trailing EPS
$-0.56
Book Value
$1.03
ROE
-48.4%
ROA
-24.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,826,000 | -70,260,000 | -64,923,000 | 160,460,000 | 57,378,000 | — | -47,113,000 |
| Dec 2024 | 18,720,000 | -50,613,000 | -132,065,000 | 220,327,000 | 64,773,000 | — | -20,075,000 |
| Dec 2023 | 31,249,000 | -116,314,000 | -88,481,000 | 197,405,000 | 40,226,000 | — | -78,325,000 |
| Dec 2022 | 29,752,000 | -85,154,000 | -86,908,000 | 254,596,000 | 56,975,000 | — | -67,567,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.73
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMMX | Immix Biopharma, Inc. | $629.32M | $8.84 | — |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $641.99M | $3.90 | — |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $646.08M | $4.38 | — |
| CRMD | CorMedix Inc. | $648.80M | $8.27 | — |
| ZVRA | ZEVRA THERAPEUTICS, INC. | $610.07M | $10.32 | — |
News headlines (Yahoo Finance, 1h cache)
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
2026-05-08 12:30 · Yahoo
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
2026-05-07 12:50 · Yahoo
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
2026-05-07 10:59 · Yahoo
Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates
2026-05-05 22:05 · Yahoo
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
2026-05-04 10:04 · Yahoo
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus
2026-04-28 14:17 · Yahoo
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Ant
2026-04-28 10:30 · Yahoo
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
2026-04-27 20:45 · Yahoo
Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming
2026-04-14 22:04 · Yahoo
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
2026-04-08 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.